CTN 012
Alternative Names: CTN-012Latest Information Update: 01 Sep 2024
At a glance
- Originator Centenaire Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Bladder cancer
Most Recent Events
- 29 Aug 2024 CTN 012 is available for licensing as of 29 Aug 2024. https://www.ctnbio.com/partnering (Centenaire Biosciences website, August 2024)
- 29 Aug 2024 Preclinical trials in Bladder cancer in South Korea (Parenteral), prior to August 2024 (Centenaire Biosciences pipeline, August 2024)